JP2022513642A - バイオテクノロジー的に重要な細菌、クロストリジウム・セルロリティクム(Clostridium cellulolyticum)由来のCas9タンパク質に基づく、DNAカット手段 - Google Patents
バイオテクノロジー的に重要な細菌、クロストリジウム・セルロリティクム(Clostridium cellulolyticum)由来のCas9タンパク質に基づく、DNAカット手段 Download PDFInfo
- Publication number
- JP2022513642A JP2022513642A JP2021529802A JP2021529802A JP2022513642A JP 2022513642 A JP2022513642 A JP 2022513642A JP 2021529802 A JP2021529802 A JP 2021529802A JP 2021529802 A JP2021529802 A JP 2021529802A JP 2022513642 A JP2022513642 A JP 2022513642A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- dna
- protein
- amino acid
- double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
組換えCcCas9タンパク質を得るため、その遺伝子をプラスミドpET21a内にクローニングした。生じたプラスミドCcCas9_pET21aによって、大腸菌Rosetta細胞を形質転換した。プラスミドを所持する細胞をOD_600=0.6の光学密度まで増殖させ、次いで、1mM濃度までIPTGを添加することによって、CcCas9遺伝子の発現を誘導した。細胞を25℃で4時間インキュベーションした後、溶解した。組換えタンパク質を以下のように:アフィニティクロマトグラフィ(NiNTA)により、そしてSuperdex 200カラム上のタンパク質サイズ排除により、2段階で精製した。Amicon 30kDaフィルターを用いて、生じたタンパク質を濃縮した。その後、マイナス80℃でタンパク質を凍結し、そしてin vitro反応に用いた。
1xCutSmart緩衝液
400nM CcCas9
100nM DNAライブラリー
2μM crRNA
2μM tracrRNA
総反応体積は20μlであった。
カットの結果、ライブラリー断片の部分は、約50塩基対(bp)および324bpの長さを有する2つの部分に分割された。対照試料として、Casエフェクター複合体の本質的な構成要素であるcrRNAが添加されていない反応を用いた。
1xCutSmart緩衝液
400nM CcCas9
20nM DNA
2μM crRNA
2μM tracrRNA
インキュベーション時間は30分間であり、反応温度は45℃であった。実験結果は、CcCas9のPAM配列をNNNNGNA-3’と確認した。最も保存されたアミノ酸は、5位のGであった(図4を参照されたい)。
実施例1. 多様なDNAターゲットのカットにおけるCcCas9タンパク質の活性の試験。
CcCas9タンパク質の温度範囲を決定するため、異なる温度条件下で、DNAターゲットのin vitroカットに対する実験を行った。
クロストリジウム属に属する近縁生物由来のCas9タンパク質。これまでに、クロストリジウム属では、II型CRISPR Cas系は1つしか見出されておらず、これはクロストリジウム・ペルフリンゲンス(Clostridium perfringens)由来のCas9 CRISPR Cas系である(Maikova Aら, New Insights Into Functions and Possible Applications of Clostridium difficile CRISPR-Cas System. Front Microbiol. 2018 Jul 31;9:1740)。
トレーサーRNA発現カセットは、以下のようになる:
プラスミドDNAを精製し、そしてLipofectamine2000試薬(Thermo Fisher Scientific)を用いて、ヒトHEK293細胞内にトランスフェクションする。細胞を72時間インキュベーションし、その後、ゲノムDNA精製カラム(Thermo Fisher Scientific)を用いて、そこからゲノムDNAを抽出する。定向性二本鎖切断、その後、その修復によりターゲット部位で行われたDNA中の挿入/欠失の数を決定するため、Illuminaプラットフォーム上で配列決定することによって、ターゲットDNA部位を分析する。
本発明で特徴づけられる細菌クロストリジウム・セルロリティクム由来のCcCas9ヌクレアーゼは、以前特徴づけられたCas9タンパク質に比較して、いくつかの利点を有する。
本発明は、開示する態様に言及して記載されてきているが、当業者は、詳細に記載される特定の態様が、本発明を例示する目的のために提供されており、そしていかなる意味でも本発明の範囲を限定するとは見なされないことを認識するであろう。本発明の精神から逸脱することなく、多様な修飾を行ってもよいことが理解されるであろう。
Claims (5)
- DNA分子中のヌクレオチド配列5’-NNNNGNA-3’の直前に位置する、前記DNA分子中の二本鎖切断を形成するための、配列番号1のアミノ酸配列を含むか、または配列番号1のアミノ酸配列に少なくとも95%同一であり、そして非保存性アミノ酸残基でのみ配列番号1と異なるアミノ酸配列を含む、タンパク質の使用。
- 37℃~65℃の温度で、DNA分子中に二本鎖切断が形成されることで特徴づけられる、請求項1記載のタンパク質の使用。
- タンパク質が配列番号1のアミノ酸配列を含む、請求項1記載のタンパク質の使用。
- 配列5’-NNNNGNA-3’に直接隣接する、単細胞または多細胞生物のゲノムDNA配列中に二本鎖切断を生成するための方法であって、当該生物の少なくとも1つの細胞内に、有効量の:a)配列番号1のアミノ酸配列を含むタンパク質、または配列番号1のアミノ酸配列を含むタンパク質をコードする核酸、並びにb)ヌクレオチド配列5’-NNNNGNA-3’にすぐ隣接する生物のゲノムDNA領域のヌクレオチド配列と二重鎖を形成し、そして二重鎖形成後に前記タンパク質と相互作用する配列を含むガイドRNA、または前記ガイドRNAをコードするDNA配列、を導入する工程を含む、
ここで、前記タンパク質と前記ガイドRNAおよびヌクレオチド配列5’-NNNGNA-3’の相互作用が、配列5’-NNNNGNA-3’に直接隣接するゲノムDNA配列中の二本鎖切断の形成を生じる
前記方法。 - ガイドRNAと同時に、外因性DNA配列の導入をさらに含む、請求項4記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018141524 | 2018-11-26 | ||
RU2018141524A RU2712497C1 (ru) | 2018-11-26 | 2018-11-26 | Средство разрезания ДНК на основе Cas9 белка из биотехнологически значимой бактерии Clostridium cellulolyticum |
PCT/RU2019/050229 WO2020111983A2 (ru) | 2018-11-26 | 2019-11-26 | Средство разрезания днк на основе cas9 белка из биотехнологически значимой бактерии clostridium cellulolyticum |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513642A true JP2022513642A (ja) | 2022-02-09 |
JP7698578B2 JP7698578B2 (ja) | 2025-06-25 |
Family
ID=69625021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021529802A Active JP7698578B2 (ja) | 2018-11-26 | 2019-11-26 | バイオテクノロジー的に重要な細菌、クロストリジウム・セルロリティクム(Clostridium cellulolyticum)由来のCas9タンパク質に基づく、DNAカット手段 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220002692A1 (ja) |
EP (1) | EP3889269A4 (ja) |
JP (1) | JP7698578B2 (ja) |
KR (1) | KR20210118069A (ja) |
CN (1) | CN113785055B (ja) |
AU (1) | AU2019388420B2 (ja) |
BR (1) | BR112021010185A2 (ja) |
CA (1) | CA3121088A1 (ja) |
CL (1) | CL2021001382A1 (ja) |
CO (1) | CO2021006938A2 (ja) |
EA (1) | EA202191504A1 (ja) |
MA (1) | MA53577B1 (ja) |
MX (1) | MX2021006119A (ja) |
PE (1) | PE20212079A1 (ja) |
PH (1) | PH12021551198A1 (ja) |
RU (1) | RU2712497C1 (ja) |
WO (1) | WO2020111983A2 (ja) |
ZA (1) | ZA202103578B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
RU2722934C1 (ru) | 2019-06-11 | 2020-06-05 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из бактерии pasteurella pneumotropica |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016537028A (ja) * | 2013-11-18 | 2016-12-01 | クリスパー セラピューティクス アーゲー | Crispr−casシステムの材料及び方法 |
WO2017222773A1 (en) * | 2016-06-20 | 2017-12-28 | Pioneer Hi-Bred International, Inc. | Novel cas systems and methods of use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11458157B2 (en) * | 2011-12-16 | 2022-10-04 | Targetgene Biotechnologies Ltd. | Compositions and methods for modifying a predetermined target nucleic acid sequence |
LT2800811T (lt) * | 2012-05-25 | 2017-09-11 | The Regents Of The University Of California | Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr |
US8697359B1 (en) * | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
EP2922393B2 (en) * | 2013-02-27 | 2022-12-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Gene editing in the oocyte by cas9 nucleases |
ES2749624T3 (es) * | 2013-03-14 | 2020-03-23 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
US9938521B2 (en) * | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
DK3145934T5 (da) * | 2014-05-19 | 2020-11-30 | Pfizer | Substituerede-6,8-dioxabicyclo[3.2.1]octan-2,3-diol-forbindelser som ASGPR-targeteringsmidler |
EP3204496A1 (en) * | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
WO2016186946A1 (en) * | 2015-05-15 | 2016-11-24 | Pioneer Hi-Bred International, Inc. | Rapid characterization of cas endonuclease systems, pam sequences and guide rna elements |
GB201510296D0 (en) * | 2015-06-12 | 2015-07-29 | Univ Wageningen | Thermostable CAS9 nucleases |
WO2019051097A1 (en) * | 2017-09-08 | 2019-03-14 | The Regents Of The University Of California | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME |
WO2019123430A1 (en) * | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
JP7402163B2 (ja) * | 2017-12-21 | 2023-12-20 | クリスパー セラピューティクス アーゲー | 2a型アッシャー症候群の処置のための材料および方法 |
WO2020092553A1 (en) * | 2018-10-31 | 2020-05-07 | The Regents Of The University Of California | Methods and kits for identifying cancer treatment targets |
-
2018
- 2018-11-26 RU RU2018141524A patent/RU2712497C1/ru active
-
2019
- 2019-11-26 CA CA3121088A patent/CA3121088A1/en active Pending
- 2019-11-26 MA MA53577A patent/MA53577B1/fr unknown
- 2019-11-26 PE PE2021000760A patent/PE20212079A1/es unknown
- 2019-11-26 BR BR112021010185A patent/BR112021010185A2/pt unknown
- 2019-11-26 KR KR1020217019947A patent/KR20210118069A/ko active Pending
- 2019-11-26 MX MX2021006119A patent/MX2021006119A/es unknown
- 2019-11-26 CN CN201980090346.6A patent/CN113785055B/zh active Active
- 2019-11-26 WO PCT/RU2019/050229 patent/WO2020111983A2/ru active Application Filing
- 2019-11-26 AU AU2019388420A patent/AU2019388420B2/en active Active
- 2019-11-26 US US17/296,597 patent/US20220002692A1/en active Pending
- 2019-11-26 EP EP19888557.6A patent/EP3889269A4/en active Pending
- 2019-11-26 EA EA202191504A patent/EA202191504A1/ru unknown
- 2019-11-26 JP JP2021529802A patent/JP7698578B2/ja active Active
-
2021
- 2021-05-25 PH PH12021551198A patent/PH12021551198A1/en unknown
- 2021-05-26 CL CL2021001382A patent/CL2021001382A1/es unknown
- 2021-05-26 CO CONC2021/0006938A patent/CO2021006938A2/es unknown
- 2021-05-26 ZA ZA2021/03578A patent/ZA202103578B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016537028A (ja) * | 2013-11-18 | 2016-12-01 | クリスパー セラピューティクス アーゲー | Crispr−casシステムの材料及び方法 |
WO2017222773A1 (en) * | 2016-06-20 | 2017-12-28 | Pioneer Hi-Bred International, Inc. | Novel cas systems and methods of use |
Non-Patent Citations (2)
Title |
---|
KARVELIS ET AL., GENOME BIOLOGY, vol. 16, no. 253, JPN6023044147, 2015, ISSN: 0005524272 * |
LEENAY ET AL., MOLECULAR CELL, vol. 62, no. 1, JPN6023044148, 2016, pages 137 - 147, ISSN: 0005524271 * |
Also Published As
Publication number | Publication date |
---|---|
AU2019388420B2 (en) | 2025-03-27 |
CN113785055A (zh) | 2021-12-10 |
MA53577A1 (fr) | 2022-02-28 |
KR20210118069A (ko) | 2021-09-29 |
MA53577B1 (fr) | 2022-10-31 |
CN113785055B (zh) | 2025-06-20 |
JP7698578B2 (ja) | 2025-06-25 |
MX2021006119A (es) | 2021-07-07 |
CO2021006938A2 (es) | 2021-09-20 |
CA3121088A1 (en) | 2020-06-04 |
PE20212079A1 (es) | 2021-10-28 |
AU2019388420A1 (en) | 2021-07-22 |
CL2021001382A1 (es) | 2022-01-07 |
US20220002692A1 (en) | 2022-01-06 |
WO2020111983A2 (ru) | 2020-06-04 |
BR112021010185A2 (pt) | 2021-12-28 |
RU2712497C1 (ru) | 2020-01-29 |
WO2020111983A3 (ru) | 2020-07-23 |
EP3889269A2 (en) | 2021-10-06 |
PH12021551198A1 (en) | 2021-10-25 |
EP3889269A4 (en) | 2022-08-31 |
EA202191504A1 (ru) | 2021-09-09 |
ZA202103578B (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12123014B2 (en) | Class II, type V CRISPR systems | |
KR20230021657A (ko) | Ruvc 도메인을 포함하는 효소 | |
JP7698578B2 (ja) | バイオテクノロジー的に重要な細菌、クロストリジウム・セルロリティクム(Clostridium cellulolyticum)由来のCas9タンパク質に基づく、DNAカット手段 | |
JP7698579B2 (ja) | デフルビーモナス属(Defluviimonas)種由来のCas9タンパク質に基づくDNAカット手段 | |
Dong et al. | A single digestion, single-stranded oligonucleotide mediated PCR-independent site-directed mutagenesis method | |
EA042517B1 (ru) | Средство разрезания днк | |
OA20196A (en) | DNA-cutting agent. | |
JP7708752B2 (ja) | 細菌パスツレラ・ニューモトロピカ(Рasteurella pneumotropica)由来Cas9タンパク質の使用 | |
RU2788197C1 (ru) | Средство разрезания ДНК на основе Cas9 белка из бактерии Streptococcus uberis NCTC3858 | |
RU2778156C1 (ru) | Средство разрезания ДНК на основе Cas9 белка из бактерии Capnocytophaga ochracea | |
JP7621281B2 (ja) | 細菌、肺パスツレラ菌(Pasteurella pneumotropica)由来のCas9タンパク質に基づくDNAカット剤 | |
RU2791447C1 (ru) | Средство разрезания ДНК на основе ScCas12a белка из бактерии Sedimentisphaera cyanobacteriorum | |
US20250059568A1 (en) | Class ii, type v crispr systems | |
OA20197A (en) | DNA-cutting agent. | |
HK40063723A (en) | Dna-cutting agent | |
EA041935B1 (ru) | СРЕДСТВО РАЗРЕЗАНИЯ ДНК НА ОСНОВЕ Cas9 БЕЛКА ИЗ БАКТЕРИИ Pasteurella Pneumotropica | |
OA20443A (en) | DNA-cutting agent based on CAS9 protein from the bacterium pasteurella pneumotropica | |
EA041933B1 (ru) | Средство разрезания днк | |
Zhou et al. | Efficient and markerless gene integration with SlugCas9-HF in Kluyveromyces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240123 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240911 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250430 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250516 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7698578 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |